✨ Medicines Act Notices
NEW ZEALAND GAZETTE
No. 169
Health
Medicines Act 1981
Consent to the Distribution of Changed Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the Act and are set out in the Schedule hereto:
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| Orciprenaline sulphate 0.75 mg per dose | Spray, oral, metered dose | Boehringer Ingelheim KG., Ingelheim am Rhein, Germany | Alupent Inhaler |
| Ciprofloxacin hydrochloride 58.22 mg/mL, 116.44 mg/mL equivalent to 50 mg/mL, 100 mg/mL ciprofloxacin and diluent | Microcapsules for suspension | Bayer AG., Leverkusen, Germany | Ciproxin Suspension |
| Dalteparin sodium 10,000 IU in 1 mL, 4 mL | Injection, ampoule | Pharmacia & Upjohn, Stockholm, Sweden | Fragmin |
| Dalteparin sodium 2,500 IU in 0.2 mL, 25,000 IU/mL in 0.2 mL, 0.4 mL, 0.5 mL, 0.6 mL, 0.72 mL | Injection, prefilled syringe | Pharmacia & Upjohn, Stockholm, Sweden | Fragmin |
| Dalteparin sodium 10,000 IU in 1 mL, 4 mL | Injection, ampoule | Pharmacia & Upjohn, Stockholm, Sweden | Fragmin |
| Dalteparin sodium 2,500 IU in 0.2 mL, 25,000 IU/mL in 0.2 mL, 0.4 mL, 0.5 mL, 0.6 mL, 0.72 mL | Injection, prefilled syringe | Pharmacia & Upjohn, Stockholm, Sweden | Fragmin |
| Lenograstim 13.4 MIU | Injection, powder, vial | Chugai Pharmaceutical Co Limited, Utsonomiya, Tochigi, Japan | Granocyte 13 |
| Lenograstim 33.6 MIU | Injection, powder, vial | Chugai Pharmaceutical Co Limited, Utsonomiya, Tochigi, Japan | Granocyte 34 |
| Human chorionic gonadotrophin 500 IU, 1500 IU, 5000 IU; sodium chloride as diluent | Injection, powder for, ampoule; Diluent, ampoule | Organon International BV., Oss, The Netherlands | Pregnyl |
| Finasteride 1 mg | Tablet, film coated | Merck Sharp & Dohme Limited, Hoddesdon, Hertfordshire, England; Merck Sharp & Dohme Limited, Cramlington, Northumberland, England and Merck Sharp & Dohme (Australia) Pty Limited, South Granville, New South Wales, Australia | Propecia |
| Epoetin beta 1000 IU, 2000 IU, 5000 IU, 10,000 IU equivalent to 8.3 µg, 16.6 µg, 41.5 µg and 83 µg epoetin; and water for injections as diluent | Injection, powder for, vial; Diluent, ampoule | Boehringer Mannheim GmbH., Mannheim, Germany | Recormon |
| Vigabatrin 500 mg, 1 g | Powder, oral, sachet | Marion Merrell Dow France SA., Bourgoin-Jallieu Cedex, France | Sabril |
Dated this 30th day of November 1997.
G. R. BOYD, Chief Advisor, Regulation and Safety, pursuant to delegation given by the Minister of Health on 20 February 1997.
go8802
Provisional Consent to the Distribution of a New Medicine
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Next Page →
PDF embedding disabled (Crown copyright)
View this page online at:
VUW Te Waharoa —
NZ Gazette 1997, No 169
NZLII —
NZ Gazette 1997, No 169
✨ LLM interpretation of page content
🏥 Consent to the Distribution of Changed Medicines
🏥 Health & Social Welfare30 November 1997
Medicines Act, Distribution Consent, Changed Medicines, Pharmaceuticals
- G. R. Boyd, Chief Advisor, Regulation and Safety
🏥 Provisional Consent to the Distribution of a New Medicine
🏥 Health & Social WelfareMedicines Act, Provisional Consent, New Medicine, Pharmaceuticals